Long-acting antiviral agents for HIV treatment
نویسندگان
چکیده
PURPOSE OF REVIEW Long-acting antiretroviral (ARV) agents are currently under development for the treatment of chronic HIV infection. This review focuses on data recently produced on injectable ARVs for patients living with HIV/AIDS and on the patients' perspectives on the use of these agents. RECENT FINDINGS Crystalline nanoparticle formulations of the nonnucleoside reverse transcriptase inhibitor rilpivirine (TMC278) and of the HIV-1 integrase strand transfer inhibitor cabotegravir (GSK1265744) have progressed into phase II clinical trials as injectable maintenance therapy for patients living with HIV/AIDS with an undetectable viral load. SUMMARY Phase II studies evaluating the coadministration of rilpivirine and cabotegravir intramuscularly to HIV-infected individuals with an undetectable viral load are currently underway. Rilpivirine and cabotegravir are characterized by different mechanisms of action against HIV and a favorable drug interaction profile, providing a rationale for coadministration. The high potency and low daily dosing requirements of oral cabotegravir and rilpivirine facilitate long-acting formulation development. Intramuscular dosing is preceded by an oral lead-in phase to assess safety and tolerability in individual participants. In addition to assessing the safety of injectable therapies in ongoing studies, it will be important to evaluate whether differences in drug adherence between injectable and oral therapies lead to different virologic outcomes, including rates of virologic failure and the emergence of resistance. Long-acting formulations may be associated with challenges, such as the management of adverse effects with persistent drug concentrations and the risk of virologic resistance, as drug concentrations decline following discontinuation.
منابع مشابه
الگوهای جدید درمانی برای عفونت ویروس هپاتیت C
Hepatitis C virus (HCV) infection has affected approximately 180 million people across the world. In most cases, HCV-infection remains chronic, which expose patients at high risk of cirrhosis and hepatocellular carcinoma. The rates of disease incidence and mortality diminish as a result of successful treatment of HCV infection. Until the recent years, despite the associated toxicities and l...
متن کاملHIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
Therapy for human immunodeficiency virus (HIV) and chronic hepatitis C has evolved over the past decade, resulting in better control of infection and clinical outcomes; however, drug-drug interactions remain a significant hazard. Joint recommendations from the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America regarding drug-drug interactions bet...
متن کاملBarriers to Hepatitis C Treatment in HIV co-infected Patients in the Era of New Direct-Acting Antiviral Therapy
متن کامل
Treatment Options for HCV Genotype-4
For the last three decades, HCV infection had been a challenging health problem due to high prevalence rate, fatal complications and till recently the lack of effective treatment. In the pre directly acting agents (DAAs) era, the interferon-ribavirin based treatment was of limited success in the clearance of the virus compounded by major side effects that caused significant morbidity and poor q...
متن کاملLiver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection
Current hepatitis C virus (HCV) treatment guidelines recommend treating HCV/human immunodeficiency virus (HIV)-coinfected individuals similar to HCV-monoinfected individuals. Recently inferior response rates to direct acting antiviral (DAA) therapy in HCV/HIV coinfection have been reported. Our German hepatitis C cohort (GECCO) cohort data show that coinfected patients with liver cirrhosis are ...
متن کامل